Twist Bioscience (TWST) investor relations material

Business Overview and Technology

• Miniaturized DNA synthesis on silicon chips enables scalable production of millions of DNA pieces, expanding into RNA and protein products.

• Three business groups—SynbioWrite, NGS Read, and Biopharma Drug Discovery Services—leverage a unified silicon chip platform for diverse life sciences solutions.

• Standardized, automated, and digitized production facilities, supported by a $1B infrastructure investment, drive operational efficiency and industrialized customization.

• Direct sales, e-commerce, and OEM channels expand customer reach and support industrialized reagent production.

• Company culture emphasizes technical expertise, customer understanding, high performance, and a diverse team with strong research and regulatory scale.

Financial Performance and Profitability

• Revenue and gross margin have grown significantly, with gross margin improving from 34.4% in FY23Q3 to 53.4% in FY25Q3.

• Adjusted EBITDA loss narrowed from $(29.6)M in Q3 2023 to $(8.0)M in Q3 2025, with breakeven targeted by end of fiscal 2026.

• Operating expenses, including SG&A and R&D, have remained stable, supporting operational leverage and shrinking losses.

• 75-80% of incremental revenue is dropping to gross margin, supporting profit expansion and disciplined capital allocation.

• Non-GAAP financial measures supplement GAAP results, with reconciliations provided.

Synbio Business Trends

• Synbio revenue grew 7% in Q3, nearly 20% excluding a large prior-year order, outpacing peers.

• Market share gains are driven by differentiated products in speed, quality, and price, despite funding headwinds.

• Express portfolio covers most gene products, offering five-day delivery and flexible pricing.

• Customer ramp was slower than expected, but satisfaction and repeat business remain strong.

• Product innovation continues to build on silicon chip investments, enhancing customer value.